Radioimmunoconjugates for use in the treatment of bone marrow-related disorders - Patent Application 20070123333

JP7580919B2Active Publication Date: 2024-11-12THERAPHARM GMBH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2019560476
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-01-23
Filing Date
2018-01-23
Publication Date
2024-11-12
Estimated Expiration
2038-01-23

Smart Images

  • Figure 0007580919000007
    Figure 0007580919000007
  • Figure 0007580919000008
    Figure 0007580919000008
  • Figure 0007580919000009
    Figure 0007580919000009
Patent Text Reader

Abstract

The present invention relates to the use of radioimmunoconjugates for the treatment of bone marrow-related diseases, particularly AL amyloidosis.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Detailed Description of the Invention The present invention relates to the use of radioimmunoconjugates for the treatment of bone marrow-related diseases, in particular AL amyloidosis.

[0002] 2. Background of the Invention Bone marrow is a flexible tissue found inside bones. It is responsible for the production of red blood cells, white blood cells, myeloid cells, plasma cells, and platelets. Bone marrow contains stem cells, which are primitive cells that can turn into any desired cell in the body. When needed, stem cells differentiate to become specific types of cells. Only mature cells are released from the bone marrow into the bloodstream.

[0003] Bone marrow-related disorders are usually associated with abnormal production of mature blood cells or progenitor or predecessor immature cells.

[0004] In one embodiment of the present invention, the bone marrow-related disease can be treated by stem cell transplantation, for example, autologous stem cell transplantation or allogeneic stem cell transplantation. In one aspect of the present invention, the bone marrow-related disease can be treated by hematopoietic stem cell transplantation. Stem cell transplantation, particularly hematopoietic stem cell transplantation, is used in certain diseases to replace deficiencies, for example, at the metabolic level, immune level, genetic level, or malignant transformation level of bone marrow.

[0005] In AL amyloidosis, an abnormal neoplastic clone of plasma cells in the bone marrow overproduces monoclonal immunoglobulin light chains that self-assemble and deposit in organs, causing organ dysfunction. The deposits have a characteristic beta-pleated secondary structure that is seen by electron microscopy as linear, unbranched fibrils of 8-10 nm. Nearly any organ or combination of organs may be affected, except the brain.

[0006] AL amyloidosis is diagnosed by Congo red staining of tissue biopsy specimens, which show pathological apple green dichroism under polarized light. Recently, radiolabeled serum amyloid P scintigraphy (SAP) has been developed at the UK National Amyloidosis Centre as a tool for non-invasive imaging and monitoring of amyloid deposits, unequivocally demonstrating that amyloid deposits of all kinds exist in a state of dynamic turnover and can regress when the amount of the respective fibril precursor protein is sufficiently reduced.

[0007] AL amyloidosis has a lifetime incidence and is the cause of death in the UK in between 0.5 and 1 per 1000 people. It occurs equally in men and women and the median age at diagnosis is 65 years. It is inexorably progressive without treatment and until recently the median survival was only 6-15 months.

[0008] After the immunoglobulin nature of AL amyloidosis deposits was established, case reports claiming beneficial responses to cytotoxic therapy appeared in the literature. A prospective randomized trial of 219 patients by the Mayo Clinic group systematically compared the efficacy of oral melphalan and prednisolone (MP) with an active placebo, colchicine. Median survival was 17 and 8.5 months in the MP and colchicine groups, respectively, providing the first strong evidence of the benefit of cytotoxic therapy in AL amyloidosis (Kyle et al., The New England journal of medicine, 1997; 336(17): 1202-7). To identify which patients with AL amyloidosis were likely to derive the greatest benefit from treatment with MP, investigators at the Mayo Clinic reported a long-term follow-up of 153 patients who received this treatment for a planned period of 24 to 36 months (Gertz et al., Journal of clinical oncology, 1999; 17(1): 262-7). Using strict response criteria that included complete disappearance of pretreatment monoclonal protein in serum or urine along with improvement of organ dysfunction, 18% of patients responded. The median survival time of responders was 89.4 months, and the median time to response was 11.7 months. However, one-quarter of responders died of myelodysplasia or acute leukemia.

[0009] The relatively poor and slow response to MP in AL amyloidosis has prompted interest in the use of high-dose melphalan therapy and stem cell transplantation (ASCT). This was first reported in 1996, with a series of 25 patients reported shortly thereafter by Comenzo and colleagues (Comenzo et al., Blood, 1998; 91(10): 3662-70). Several centers subsequently reported clinical benefit in approximately 60% of patients who survived surgery. However, treatment-related mortality was fairly consistently higher in amyloid patients than in myeloma patients. In two studies from one US center, 100-day mortality was approximately 14% and in two European centers it was approximately 40%, reflecting the dysfunction of multiple organ systems due to amyloid. These findings have also prompted interest in alternative, less toxic therapies, highlighting the need for improved patient selection for ASCT and improved clinical management before and after transplantation.

[0010] In the United States, patient selection has been refined (Comenzo et al., Blood, 2002; 99(12): 4276-82), and ASCT remains the therapeutic "gold standard" for treating AL amyloidosis. Results of a long-term follow-up study of 701 consecutive patients with systemic AL amyloidosis were recently reported by the Boston group; 394 (56%) were considered eligible for ASCT, of which 82 did not progress due to patient selection or disease progression (Skinner et al., Ann Intern Med, 2004; 140(2): 85-93). Of the 312 patients who initiated treatment, treatment-related mortality (TRM) was 13%, and the median survival for the entire cohort was 4.6 years. The median survival for non-eligible patients was only 4 months. Interestingly, Dispenzieri et al. looked at data on AL amyloidosis patients treated at the Mayo Clinic from 1983 to 1997 and identified 229 patients who would have been eligible for ASCT today. Their median survival was 42 months, with 5- and 10-year survival rates of 36% and 15%, respectively, suggesting that the survival benefit from ASCT is due in part to patient selection rather than to a specific treatment. A French randomized trial further cast doubt on the role of ASCT in AL amyloidosis because of the high treatment-related mortality of about 22%, and because of the lack of improved overall survival in the ASCT group versus oral melphalan dexamethasone chemotherapy in a landmark analysis (Jaccard et al., The New England journal of medicine, 2007; 357(11): 1083-93). However, the high TRM and lower-than-expected responses lead to many criticisms of this study. The role of ASCT therefore remains unclear and practice at the UK National Amyloidosis Centre has in recent years rarely recommended ASCT as first-line therapy, although it has considered its role in patients who have not responded adequately to first-line treatment with intermediate-dose chemotherapy regimens such as vincristine, adriamycin and dexamethasone (VAD).The outcome of all 92 patients with AL amyloidosis seen at the UK National Amyloidosis Centre who underwent ASCT between 1994 and 2004 has recently been determined; median overall survival for the entire cohort was 63 months, with TRM of 23%, although retrospective analysis identified a subset of patients without TRM (Goodman et al., Haematologica / The Hematology Journal, 2005; 90(s1): 201). Factors identified from the NAC study led to refinement of patient selection criteria in the UK, and data from 2003-2011 from 83 patients undergoing ASCT revealed a TRM of 6%.

[0011] Even in highly selected patient groups, TRM and treatment-emergent morbidity persists, with most of the treatment-emergent morbidity due to high-dose melphalan toxicity leading to mucositis, drug-induced hematologic end-organ damage, or cytopenic complications.

[0012] Before patients receive their own hematopoietic stem cells (autologous transplant; ASCT) or those of a genetically related human donor (allogeneic transplant), they must be administered high-dose melphalan treatment. Such conditioning is a critical step to eliminate both the patient's hematopoietic system and malignant stem cells, preparing the patient for successful engraftment and producing optimal therapeutic outcomes.

[0013] Due to the toxicity of the high-dose melphalan conditioning step, ASCT may only be applied to eligible patients who are in relatively good physical condition, primarily those younger than 65 years and / or those with good organ function.

[0014] Even with careful selection of so-called eligible patients, there is still a single-digit rate of treatment-related mortality (TRM), mainly caused by various toxicities and direct or indirect consequences of high-dose melphalan treatment. Clearly, there is a constant need for selective treatment methods that allow reducing the treatment-related mortality caused mainly by high-dose melphalan treatment.

[0015] A number of radioimmunoconjugates (RICs) using monoclonal antibodies selective for specific antigens such as CD45, CD33, CD20, CD19 and CD66 have been investigated for bone marrow conditioning before transplantation in hematological malignancies such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and degenerative myelodysplasia (MDS). (Matthews D. et al., Blood, 1999, 94: 1237-1247; Jurcic JG, Cancer Biother Radiopharm., 2000, 15: 319-326; Bunjes D. et al., Blood, 2001, 98: 565-572). Radioimmunoconjugates were applied in addition to standard conditioning regimens. However, most of these radioimmunoconjugates show nonselective organ uptake. The causes of this non-targeted uptake of radioimmunoconjugates are multifactorial and include specific and non-specific uptake and instability of the immunoconjugates in vivo. Known RICs exhibit severe dose-limiting toxicity in the liver, lungs, and kidneys, depending on the selectivity of the antibody used and / or the stability of the bound radiolabel (e.g., the anti-CD66 mAb studied by Bunjes et al. 188 Re-labeled molecules, Blood, 2001, 98: 565-572). Unfortunately, only a small fraction of the injected dose reaches the desired target (Karger, Contrib. Oncol. Basel, 1992, 43, 100-145). This limitation is the main reason for many failed clinical studies in the field of targeted antibodies, where dose-limiting toxicity did not allow to produce the desired therapeutic effect.

[0016] In International Publication No. 2007 / 062855 (WO 2007 / 062855), 90 A method for the treatment of multiple myeloma using a CD66 monoclonal antibody radiolabeled with Y has been described. The radioimmunoconjugate described selectively targets the bone marrow and spleen, without accumulating in the liver or kidneys. In a first step,111 Dosimetry studies using In-labeled anti-CD66 radioimmunoconjugates were performed to determine the suitability of each patient for treatment. Patients with multiple myeloma who showed good dosimetry (>90%) were: 90 The patients were conditioned with Y-labeled anti-CD66 (graded from 5MBq / kg lbw to 45MBq / kg lbw). After this initial conditioning step, the patients received standard high-dose melphalan therapy followed by autologous hematopoietic stem cell transplantation.

[0017] Results of a randomized phase II clinical trial show that anti-CD66 antibody-targeted radiotherapy (ATRT) followed by high-dose melphalan and ASCT (arm A) showed a 50% to 50% complete regression rate compared with high-dose melphalan and ASCT (arm B), whereas the complete regression rate was only 25% in arm B. The side effect profile of both treatment arms was similar.

[0018] WO 2011 / 144744 proposes targeted radioimmunoconjugates (RIC) in combination with cytotoxic agents such as melphalan following stem cell transplantation to treat inflammatory and / or autoimmune diseases.

[0019] The inventors have unexpectedly found that targeted radioimmunotherapy in bone marrow conditioning using a RIC comprising a CD66 binding component and a radionuclide is suitable for use in treating patients, particularly human patients, suffering from bone marrow-related diseases such as AL amyloidosis without the occurrence of detectable side effects.

[0020] Thus, one aspect of the present invention is a radioimmunoconjugate (RIC) comprising a CD66 binding moiety and a radionuclide for use in the treatment of bone marrow-related diseases such as AL amyloidosis.

[0021] Thus, in accordance with the present invention, a radioimmunoconjugate (RIC) comprising a CD66 binding component and a radionuclide may be used as a pharmaceutical agent for administration in the treatment of bone marrow-related diseases such as AL amyloidosis.

[0022] In another embodiment, a radioimmunoconjugate comprising a CD66 binding component and a radionuclide may be used as a pharmaceutical agent during bone marrow conditioning, particularly prior to stem cell transplantation, more particularly prior to hematopoietic stem cell transplantation. Bone marrow conditioning may include immune ablation and bone marrow ablation to prevent graft rejection and / or reduce the number of defective cells in the bone marrow.

[0023] Bone marrow conditioning can be measured, for example, by determining bone marrow depletion using histopathological staining procedures known in the art or by assessing the degree of peripheral blood cell counts. Acceptance of transplanted cells can also be assessed as a measure of successful conditioning.

[0024] In a preferred embodiment, the subsequent stem cell transplantation can be an autologous or allogeneic transplantation.It has been shown that bone marrow conditioning according to the present invention does not cause any side effects, such as nausea and vomiting, fever, mucositis, diarrhea and sepsis, which are usually caused by bone marrow conditioning in the prior art.Therefore, the use of RIC according to the present invention in bone marrow conditioning reduces or even avoids hospitalization treatment, compared with bone marrow conditioning treatment by prior art regimes, such as high-dose chemotherapy, for example, high-dose melphalan treatment.In a preferred embodiment, RIC of the present invention is preferably used as a medicine in bone marrow conditioning without additional cytotoxic or cytostatic agents, for example, melphalan.

[0025] In another embodiment, the RICs of the invention are used as pharmaceutical agents in bone marrow conditioning with lower doses of cytotoxic or cytostatic agents compared to standard prior art doses.

[0026] The therapeutic regimen may include administration of a radionuclide suitable for imaging and / or therapeutic irradiation of bone marrow. RIC administration is preferably a pre-transplant treatment in combination with further therapy, in particular stem cell transplantation. The radionuclide of the RIC may be a therapeutically effective radionuclide. For example, the therapeutically effective radionuclide may be a β- or β / γ-emitting radionuclide, such as yttrium-90 ( 90 Y), iodine-131( 131 I), Samarium-153( 153 Sm), Holmium-166( 166 Ho), Rhenium-186( 186 Re), rhenium-188( 188 Re) or lutetium-177( 177 Lu), or an α-emitter, such as astatine-211 ( 211 At), Bismuth-212( 212 Bi), Bismuth-213( 213 Bi) or Actinium-225 ( 225 In a preferred embodiment, the therapeutically effective radionuclide can be yttrium-90 ( 90 Y).

[0027] The radionuclide of the RIC may be an imaging radionuclide, i.e., a radionuclide suitable for monitoring and / or determining the pharmacokinetics of the RIC. For example, the imaging radionuclide may be indium-111 ( 111 In), iodine-131( 131 I) or technetium-99m ( 99m In a preferred embodiment, the imaging radionuclide is indium-111 ( 111 In).

[0028] In a particularly preferred embodiment, the invention includes measuring the therapeutically effective amount of the therapeutic RIC before administration. This determination can be made individually for the subject or group of subjects to be treated, for example, based on the severity of disease progression. For example, the invention can include administration of a RIC containing an imaging radionuclide, and then administration of a RIC containing a therapeutically effective radionuclide. By first administering the imaging RIC, the effective amount of the subsequently administered therapeutic RIC can be determined and / or adjusted individually for each subject, for example, a human patient. In this embodiment, the CD66 binding component of the imaging RIC and the therapeutic RIC are preferably identical, at least in terms of CD66 binding specificity and / or affinity.

[0029] In a preferred embodiment, the imaging RIC is administered to the patient 2 to 10 days, preferably 2 to 8 days, prior to administration of the therapeutic RIC.

[0030] However, it should be noted that if sufficient patient data has been collected, e.g., in a database, to determine a therapeutically effective amount of a RIC, it may not be necessary to administer an imaging RIC prior to administration of a therapeutic RIC. Thus, further preferred embodiments of the present invention include determining a therapeutically effective amount of a RIC by evaluating existing data, e.g., from a database, in combination with, inter alia, immunohistochemical analysis of the patient's bone marrow cells.

[0031] The CD66 binding component is preferably a polypeptide comprising at least one antibody binding domain, such as an antibody, in particular a monoclonal antibody, a chimeric antibody, a humanized antibody or a recombinant antibody, such as a single chain antibody or a fragment thereof, such as a proteolytic antibody fragment, such as a Fab-, Fab'-, or F(ab)2-fragment or a recombinant antibody fragment, such as a single chain Fv-fragment.

[0032] The CD66-binding component may also be a fusion polypeptide comprising at least one antibody-binding domain and a further domain, such as an effector domain, such as an enzyme or a cytokine. The CD66-binding molecule may also be an ankyrin or scaffold polypeptide.

[0033] In a preferred embodiment, the CD66 binding component selectively binds to the human CD66 antigen or an epitope thereof, such as CD66a, b, c or e. In a particularly preferred embodiment, the CD66 binding component is the BW250 / 183 antibody. Murine, humanized and recombinant forms of this antibody are described in EP-A-0 388 914, EP-A-0 585 570 and EP-A-0 972 528, which are incorporated herein by reference.

[0034] The radionuclide is preferably attached to the CD66 binding component via a chelating agent, which is preferably a covalent bond. More preferably, the radionuclide has the formula: [(chelating agent)-(R 1 ) p -(R 2 -R 3 ) n ] m -(CD66 binding component) It binds to the CD66-binding component via the structure of where n is 0 or 1, m is 1 to 15; p is 0 or 1; R 1 and R 3-NH-CS-NH-, -NHCONH-, -NHCOCH2S-, -SS-, -NH-NH-, -NH-, -S-, -CONHNH-, -SCH2CH2COONH-, -SCH2CH2SO2-, -SCH2CH2SO2NH-, -CONH-, -O-CH2CH2O-, -CO-, -COO-, -NH-O-, -CONHO-, -S-(CH2)3C(NH)NH-, -NH-COO-, -O- and [ka] and is independently selected from the group consisting of: R 2 is C1-C18 alkylene, branched C1-C18, -CH2-C6H 10 -, p-alkylphenylene, p-phenylene, m-phenylene, p-alkyloxyphenylene, naphthylene, -[CH2CH2O] x -, -[CH2CH2SOCH2CH2] x -, -[CH2CH2SO2CH2CH2] x -or- [NHCHR4CO] y - (wherein x is 1 to 200 and y is 1 to 20), and R4 is selected from the group consisting of H-, Me-, HSCH2-, isopropyl, but-2-yl, CH3SCH2CH2-, benzyl, 1H-indol-3-yl-methyl, HOCH2-, HOOCCH2-, CH3CH(OH)-, HOOCCH2CH2-, 4-hydroxybenzyl, H2NCOCH2-, H2NCOCH2CH2-, 4-aminobut-1-yl, 2-guanidinoethyl, 1H-imidazol-5-yl-methyl and 2-methylprop-1-yl.

[0035] For example, chelating agents include diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA), 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA), 1,4,7-triazonane-N,N',N''-triacetic acid (NOTA), 2,2'-(2-(((1S,2S)-2-(bis(carboxymethyl)amino)cyclohexyl)-(carboxymethyl)amino)ethylazanediyl)diacetic acid (cyclohexano-DTPA), 2,2'-(2-(((1R,2R ... Acetic acid, 2,2'-(2-(((1S,2R)-2-(bis(carboxymethyl)amino)cyclohexyl)-(carboxymethyl)amino)ethylazanediyl)diacetic acid, 2,2'-(2-(((1R,2S)-2-(bis(carboxymethyl)amino)cyclohexyl)-(carboxymethyl)amino)ethylazanediyl)diacetic acid, 2,2',2'',2'''-(2,2'-(1S,2S)-cyclohexane-1,2-diylbis((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis(azanetriyl)tetraacetic acid, 2,2',2'',2''''-(2,2'-(1S,2R)-cyclohexane-1,2-diylbis((carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis(azanetriyl)tetraacetic acid, (1R)-1-benzyl-diethylenetriaminepentaacetic acid, (1S)-1-benzyl-diethylenetriaminepentaacetic acid, (2R)-2-benzyl-diethylenetriaminepentaacetic acid, (2S)-2-benzyl-diethylenetriaminepentaacetic acid, (2R)-2-benzyl-(3R)-3-methyl-DTPA, (2R)-2-benzyl-(3S)-3-methyl-DTPA, (2S)-2-benzyl-(3S)-3-methyl-DTPA, (2S)-2-benzyl-(3R)-3-methyl-DTPA, (2R)-2-benzyl- (4R)-4-methyl-DTPA, (2R)-2-benzyl-(4S)-4-methyl-DTPA, (2S)-2-benzyl-(4S)-4-methyl-DTPA, (2S)-2-benzyl-(4R)-4-methyl-DTPA, (1R)-1-benzyl-(3R)-3-methyl-DTPA, (1R)-1-benzyl-(3S)-3-methyl-DTPA, (1S)-1-benzyl-(3S)-3-methyl-DTPA, (1S)-1-benzyl-(3R)-3-methyl-DTPA, (1R)-1-benzyl-(4R)-4-methyl-DTPA, (1R)-1-benzyl benzyl-(4S)-4-methyl-DTPA, (1S)-1-benzyl-(4S)-4-methyl-DTPA, (1S)-1-benzyl-(4R)-4-methyl-DTPA, 2,2'-((1R,2R)-2-(((R)-2-(bis(carboxymethyl)amino)-3-phenylpropyl)(carboxymethyl)amino)cyclohexylazanediyl)diacetic acid, 2,2'-((1S,2S)-2-(((S)-2-(bis(carboxymethyl)amino)-3-phenylpropyl)(carboxymethyl)amino)cyclohexylazanediyl)diacetic acid, 2,2'-( (1R,2R)-2-(((S)-2-(bis(carboxymethyl)amino)-3-phenylpropyl)(carboxymethyl)amino)cyclohexylazanediyl)diacetic acid, 2,2'-((1S,2S)-2-(((R)-2-(bis(carboxymethyl)amino)-3-phenylpropyl)(carboxymethyl)amino)cyclohexylazanediyl)diacetic acid, 2,2'-((1R,2S)-2-(((R)-2-(bis(carboxymethyl)amino)-3-phenylpropyl)(carboxymethyl)amino)cyclohexylazanediyl)diacetic acid, 2,2'-((1S,2R)-2-(((S)-2-(bis(carboxymethyl)amino)-3-phenylpropyl)(carboxymethyl)amino)cyclohexylazanediyl)diacetic acid, 2,2'-((1S,2R)-2-(((R)-2-(bis(carboxymethyl)amino)-3-phenylpropyl)(carboxymethyl)amino)cyclohexylazanediyl)diacetic acid, 2,2'-((1R,2S)-2-(((S)-2-(bis(carboxymethyl)amino)-3-phenylpropyl)(carboxymethyl)amino)cyclohexylazanediyl)diacetic acid, (2S)-2-benzyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, (2R)-2-benzyl-1,4,7,10-tetraazacyclododecane-N,N',N'',N '''-tetraacetic acid, 6-benzyl-1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid, 2-benzyl-1,4,7-triazonane-N,N',N''-triacetic acid, benzyl-3-methyl-diethylenetriaminepentaacetic acid (2B3M-DTPA), (R)-2-amino-3-(phenyl)propyl)trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid) (Bn-CHX-A''-DTPA, also called CHX-A''-DTPA) and salts and derivatives thereof, in particular (R)-2-amino-3-(phenyl)propyl)trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid) (Bn-CHX-A''-DTPA, also called CHX-A''-DTPA) and salts thereof.

[0036] The present invention also relates to radioimmunoconjugates having the structure CD66 binding moiety-NH-CS-NH-Bn-CHX-A″-DTPA (also referred to as CD66 binding moiety-NH-CS-NH-CHX-A″-DTPA), and their formula I [ka] and their use in treating bone marrow-related diseases such as AL amyloidosis. More preferably, the radioimmunoconjugate is BW250 / 183-NH-CS-NH-Bn-CHX-A"-DTPA (also referred to as BW250 / 183-NH-CS-NH-CHX-A"-DTPA) or a salt thereof.

[0037] Administration of therapeutic RIC for treatment of human patients is preferably at a dose of about 10 MBq / kg lean body weight (lbw) or more, preferably about 15 MBq / kg lbw or more, more preferably about 20 MBq / kg lbw or more, even more preferably about 25 MBq / kg lbw or more, even more preferably about 30 MBq / kg lbw or more, even more preferably about 35 MBq / kg lbw or more. Preferably, the dose of therapeutic radioimmunoconjugate ranges up to 60 MBq / kg lbw, preferably up to 50 MBq / kg lbw, more preferably up to 45 MBq / kg lbw.

[0038] The RIC may be administered according to known methods, for example, by injection, optionally together with a pharma- ceutically acceptable carrier.

[0039] The RIC of the present invention is preferably administered as a conditioning treatment in a therapy that includes an additional step such as stem cell transplantation, in particular autologous or allogeneic stem cell transplantation, more particularly autologous stem cell transplantation. The therapeutic radioimmunoconjugate is preferably administered to the patient 6 to 16 days, preferably 6 to 12 days, prior to the stem cell transplantation.

[0040] In a further preferred embodiment, treatment of bone marrow-related diseases, such as AL amyloidosis, according to the present invention does not include administration of additional anti-tumor agents, such as melphalan, or immunosuppressants for at least 4 weeks before or after stem cell transplantation.

[0041] In a further preferred embodiment, the treatment of bone marrow-related diseases such as AL amyloidosis using a therapeutic RIC according to the invention is for administration to patients who have been treated with high-dose melphalan, followed by stem cell transplantation, but who have shown disease progression.

[0042] In a further preferred embodiment, the treatment of bone marrow-related diseases such as AL amyloidosis using a therapeutic RIC according to the present invention is intended to be administered to patients who have been treated with induction therapy, e.g., Velcade, dexamethasone, thalidomide; or Velcade, dexamethasone, cyclophosphamide; or Velcade, dexamethasone; or melphalan, prednisone; or pomalidomide, dexamethasone, but have shown disease progression.

[0043] In a further preferred embodiment, the treatment of bone marrow-related diseases such as AL amyloidosis using a therapeutic RIC according to the present invention is for administration to patients who have been treated with induction therapy (Velcade, dexamethasone, thalidomide; or Velcade, dexamethasone, cyclophosphamide; or Velcade, dexamethasone; or melphalan, prednisone; or pomalidomide, dexamethasone) and have demonstrated a hematological response to these respective therapeutic combinations.

[0044] In a further preferred embodiment, the treatment of bone marrow-related diseases, such as AL amyloidosis, with a therapeutic RIC according to the invention is for administration to patients who are ineligible for HD-melphalan prior to HSCT.

[0045] The therapeutic protocol for the treatment of bone marrow-related diseases, particularly AL amyloidosis, comprises the following steps: (a) optionally administering an imaging RIC to the patient; (b) administering a therapeutic RIC to the patient; and (c) Transplantation of autologous or allogeneic stem cells may include.

[0046] The therapeutic protocol for the treatment of bone marrow-related diseases, particularly AL amyloidosis, comprises the following steps: (a) optionally administering imaging RIC to the patient; (b) administering a therapeutic RIC to the patient; (c) optional administration of antibiotics; and (d) Transplantation of autologous or allogeneic stem cells It may consist of:

[0047] The therapeutic protocol for the treatment of bone marrow-related diseases, particularly AL amyloidosis, comprises the following steps: (a) optionally administering imaging RIC to the patient; (b) administering a therapeutic RIC to the patient; (c) optionally administering antibiotics, antifungals and / or antivirals; and (d) Transplantation of autologous or allogeneic stem cells may include.

[0048] The antibiotic according to the present invention may be a fluoroquinolone, ciprofloxacin (Cipro), levofloxacin (Levaquin / Kixin), gatifloxacin (Tequin), moxifloxacin (Avelox), ofloxacin (Ocuflox / Floxin / Floxacin), norfloxacin (Noroxin).

[0049] Virustatics according to the present invention can be acyclovir, ganciclovir, or valganciclovir.

[0050] The antifungal agent used according to the present invention may be fluconazole, amphotericin B, nystatin, natamycin, rimocidin, filipin, candicin, hamicin, perimycin, dermostatin.

[0051] A preferred treatment protocol, particularly for the treatment of bone marrow-related diseases such as AL amyloidosis, is (a) optionally, prior to step (b), administering to the patient an imaging RIC, particularly for 2 to 10 days, more particularly 2 to 8 days; (b) administering to the patient a therapeutic RIC, particularly for 6 to 16 days, more particularly 12 to 16 days, prior to step (c); (c) Transplanting the autologous or allogeneic stem cells. Includes.

[0052] A particularly preferred treatment protocol for the treatment of bone marrow-related diseases, particularly AL amyloidosis, includes: (i) optionally, prior to step (ii), 111 administering to the patient an imaging RIC of the antibody BW250 / 183 containing In, in particular for 2 to 10 days, more particularly for 2 to 8 days. (ii) prior to step (iii), 90 administering to the patient a therapeutic RIC of antibody BW250 / 183 containing Y, in particular for 6 to 16 days, more particularly for 12 to 16 days; and (iii) Transplanting autologous or allogeneic stem cells. Includes.

[0053] Surprisingly, it has been found that for the treatment of bone marrow-related diseases such as AL amyloidosis, bone marrow conditioning does not require the administration of additional anti-tumor or immunosuppressive agents such as melphalan. Thus, by treating such diseases using only radioimmunoconjugates as the conditioning agent, any side effects normally associated with standard conditioning with anti-tumor and / or immunosuppressive agents are minimized or even avoided. The present invention allows for the treatment of patients with AL amyloidosis who are not candidates for transplantation.

[0054] Furthermore, it has surprisingly been found that patients suffering from bone marrow-related diseases such as AL amyloidosis who have been treated with high dose melphalan followed by stem cell transplantation but who have shown disease progression can be treated with a therapeutic radioimmunoconjugate according to the invention followed by stem cell transplantation.

[0055] It has also been found that patients suffering from bone marrow-related diseases such as AL amyloidosis who have been treated with induction therapy but have shown progression can be treated with a therapeutic radioimmunoconjugate according to the present invention followed by stem cell transplantation.

[0056] The invention will now be explained in more detail by the following examples. [Brief description of the drawings]

[0057] [Figure 1] FIG. 1 shows the preparation of the immunoconjugate CHX-A″-DTPA-anti-CD66 monoclonal antibody. [Diagram 2] FIG. 2 shows a flow diagram of the radiolabeling process for the Indium-111 CHX-A″-DTPA-anti-CD66 formulation. [Diagram 3] FIG. 3 shows a flow diagram of the radiolabeling process for the 90 Yttrium CHX-A″-DTPA-anti-CD66 formulation. [Figure 4] FIG. 4 shows the composition of the 90 Yttrium-labeled CHX-A″-DTPA-anti-CD66 formulation. [Diagram 5] FIG. 5 shows sequential whole-body gamma images following injection of the [111In]-anti-CD66 formulation. [Figure 6] Figure 6a shows a gamma camera image after injection of an [111In]-anti-CD66 formulation, and Figure 6b shows a bremsstrahlung image after injection of an [90Y]-anti-CD66 formulation. [Figure 7] FIG. 7 shows the FLC response of patients following 90Y-anti-CD66 treatment.

[0058] Working Example material CD66 binding component Molecular Weight and Formulation The murine IgG1 kappa monoclonal antibody anti-CD66 BW 250 / 183 is a monomer with a molecular weight (MW) of 150 kDa protein, composed of IgG heavy and light chains of predicted MW (approximately 50 and 25 kDa, respectively). The antibody is also known as: INN Name:Besilesomab Chemical name: Monoclonal antibody BW 250 / 183 Laboratory code name: MAb BW 250 / 183 CAS Registry Number: 537694-98-7

[0059] Chelating Agents NCS-CHX-A''-DTPA chelating agent The synthetic bifunctional chelate used for the covalent attachment event on the antibody is synthesized by Macrocyclics (1309 Record Crossing, Dallas, TX 75235, USA). Its IUPAC name is 2,2'-(2-(((S)-1-(bis(carboxymethyl)amino)-3-(4-isothiocyanatophenyl)propan-2yl)(carboxymethyl)amino)propylazanediyl)diacetic acid, also known as isothiocyanato-(R)-2-amino-3-(phenyl)propyl)trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid (abbreviated as ITC-CHX-A''-DTPA or ITC-Bn-CHX-A''-DTPA). The low molecular weight chelate (molecular weight: 704 Da) has the following chemical formula C 26 H 34 N4O 10 It has S.3HCl and appears as a solid off-white powder. [ka]

[0060] Preparation of radioimmunoconjugates The batch size of CHX-A''-DTPA-anti-CD66 drug substance (batch no. AB012) was 122 ml (355 mg), which corresponded to a working volume of 152 ml (426 mg) of the starting monoclonal antibody formulation, anti-CD66 Mab250 / 183 (Orpegen Pharma GmbH or Glycotope Biotechnology GmbH, Germany, or Celonic, Germany). The batch size of CHX-A''-DTPA-anti-CD66 drug substance (batch no. AB013) was 250 ml (775 mg), which corresponded to a working volume of 376 ml (1051 mg) of the starting monoclonal antibody formulation, anti-CD66 Mab250 / 183 (Orpegen Pharma GmbH).

[0061] An overview of the manufacturing process and in-process control that was implemented is shown in Figure 1.

[0062] a) Thawing the material The first step in the process is the thawing of a vial of anti-CD66 Mab a specific number of times as specified in the batch record. The Mab is thawed at room temperature in a laminar flow hood (LFH) before the vials are combined into one sterile Falcon tube. An in-process QC sample is taken for size exclusion analysis to ensure that the Mab is predominantly monomeric and this result is reported.

[0063] The chelator ITC-CHX-A''-DTPA is removed from the freezer and allowed to warm to ambient temperature for a minimum of 1 hour.

[0064] b) Cross-flow ultrafiltration of Mab - diafiltration into 0.1 M sodium carbonate pH 9.0 solution The main processing step in the manufacture of drug substance processes is the cross-flow ultrafiltration / diafiltration (UF / DF) step. These cartridges are disposable, single-use, and available in several different molecular weight cut-offs for processing (Spectrum Laboratories, USA). Cartridges and UF / DF equipment are preconditioned according to the manufacturer's recommendations to remove glycerol and then sterilized using a validated autoclave sterilization cycle before use. Generally, UF / DF steps are performed to filter, diafilter (buffer exchange), and concentrate the product to predetermined specifications. Hollow fiber cartridges with a 50 kDa MW cut-off are operated within defined operating parameters (e.g., transmembrane pressure, speed in a low shear regime) that allow retention of Mabs while passing salts and other low molecular weight impurities. Cartridges and assemblies are operated in a grade A laminar flow hood in a grade B cleanroom background in a closed process.

[0065] Prior to processing, add 1:10 vol:vol of 0.01M DTPA solution to the Mab solution in the LFH (i.e., 1ml DTPA per 10ml Mab). The Mab is gently mixed and incubated at room temperature for 30 minutes. The Mab solution is introduced into the hollow fiber cross-flow assembly of the LFH and then the Mab is diafiltered with a minimum of 5 volumes of 0.1M sodium carbonate pH 9.0 until the pH is within acceptable range. An in-process QC sample is taken to ensure that the pH is within the required pH 8.9-9.2 range for the conjugate. The Mab is recovered from the hollow fiber cartridge into a sterile Falcon tube. An in-process QC sample is taken and the Mab concentration is monitored at OD 280nm.

[0066] c) Mab-chelate conjugates Calculate the amount of ITC-CHX-A''-DTPA chelator needed - 1 mg for every 5 mg of Mab to be conjugated. Carefully weigh the chelator into a sterile container before dissolving in DMSO (dissolve 1 mg of chelator per 20 μl of DMSO). Carefully add the ITC-CHX-A''-DTPA chelator to the Mab with thorough mixing (use a small amount of carbonate buffer to wash any remaining ligand out of the container and add to the Mab). Replace the lid on the Mab container and mix the solution very gently by swirling by hand. Label the tubes and leave at room temperature for 2 hours before incubating overnight at +2-8°C.

[0067] d) Cross-flow ultrafiltration of Mabs - diafiltration / concentration into acetate buffer For LFH, the Mab solution is diafiltered into 0.1 M ammonium acetate solution pH 6 until the in-process QC radiolabeling efficiency is greater than 97%. Once the radiolabeling efficiency is greater than 97%, the Mab is recovered from the hollow fiber cross-flow device into a sterile Falcon tube by releasing the transmembrane pressure. An in-process QC sample is taken, the Mab concentration is measured at OD 280 nm, and if necessary, the Mab is further diluted with acetate buffer to within the acceptable range of 2.5-3.3 mg / ml. The final Mab solution is stored at +2-8 °C.

[0068] e) Sterile filtration and filling of API into cryovials At the LFH, the product is sterile filtered using a 0.22 μM filter into a sterile Falcon tube, on a grade B background. The filters are integrity tested to ensure they are within the acceptable bubble point range. At the LFH, the product is aseptically dispensed into sterile cryovials using an autoclaved fixed volume pipette, on a grade B background. During processing, EM is performed by the operator to include continuous air particle counts. The vials are sealed and labeled according to GMP before storage below -70°C.

[0069] The bifunctional chelating CHX-A''-DTPA-anti-CD66 monoclonal antibody remains as a monomeric IgG1 of expected MW size and composition. The preparation is shown to maintain specificity for the CD66 antigen by immunoreactivity assays.

[0070] CHX-A''-DTPA-anti-CD66 monoclonal antibody is highly soluble in water, and when dissolved in ammonium acetate buffer, pH 6.0, it appears as a colorless, transparent solution with no visible particles.

[0071] formulation 111 Indium-labeled CHX-A''-DTPA-anti-CD66 preparation 111 The indium-labeled CHX-A''-DTPA-anti-CD66 formulation is manufactured in single dose units for individual patients. 111 The indium-labeled CHX-A''-DTPA-anti-CD66 preparation was incubated with an excess of 111 A maximum of 300MBq will be prepared with indium to allow for residual radioactivity losses during manufacture and delays before infusion. A dose of 185MBq ± 10% will be administered to each patient. Dosage will be calculated based on the radioactivity concentration in the vial. Residual radiolabeled product will be remeasured and adjusted for the original activity to allow accurate recording of the actual radioactivity administered to the patient. 111 A flow diagram of the radiolabeling process for the Indium-CHX-A″-DTPA-anti-CD66 formulation is shown in FIG.

[0072] 111 Indium-labeled CHX-A''-DTPA anti-CD66 formulations are radionuclides 111 It is an indium-labeled monoclonal antibody conjugated to a bifunctional chelator.

[0073] The two components of this radiolabeled antibody conjugate are: 1) CHX-A''-DTPA-anti-CD66 monoclonal antibody ("drug substance") 2) Radioactive nuclides 111 indium

[0074] Radiolabeling of the monoclonal antibody conjugate will be prepared individually for each patient by the radiopharmaceutical department at each site according to GMP guidelines and will be supplied as a sterile, pyrogen- and particle-free solution for intravenous infusion containing besilesomab (1.0-1.5 mg), diluted to 8.0 ml with 0.9% sodium chloride solution BP and labeled with indium-111 so that the final radioactive concentration at the end of synthesis is approximately 23 MBq / ml (acceptable range 20-30 MBq / ml). The volume of each batch of drug product will be approximately 8-10 ml at the end of production. The patient dose will be indicated in one 10 ml syringe.

[0075] Furthermore, radiolabeling of monoclonal antibody conjugates with In111 can be performed centrally at the radiopharmaceutical manufacturing site, and the formulations will be shipped at 4–8 °C to the respective transplant centers treating patients.

[0076] 90 Yttrium-labeled CHX-A''-DTPA-anti-CD66 formulation 90 The yttrium-labeled CHX-A″-DTPA-anti-CD66 formulation is manufactured in single dose units for individual patients. The composition of each batch / single dose unit is shown in FIG. 4. 90 The yttrium CHX-A''-anti-CD66 formulation was prepared by adding 25% or more of the 90 The vial is manufactured with yttrium. The amount actually administered to the patient will depend on the patient's lean body mass and the prescribed activity according to the protocol. The volume administered is calculated based on these factors along with the concentration of radioactivity in the vial. The remaining radiolabeled product is remeasured and adjusted for the original activity to allow for an accurate recording of the actual activity administered to the patient. 90 A flow diagram of the radiolabeling process for the yttrium CHX-A″-DTPA-anti-CD66 formulation is shown in FIG.

[0077] Radiolabeled monoclonal antibody conjugates were prepared individually for each patient by the radiopharmaceutical department at each site according to GMP guidelines and supplied as a sterile, pyrogen- and particle-free solution for intravenous infusion containing CHX-A''-DTPA anti-CD66 (1.0-1.5 mg), diluted to approximately 8.0 ml with 0.9% sodium chloride solution BP, 90 Label with yttrium so that the final radioactivity concentration at the end of the synthesis is in the range of 200-500 MBq / ml.

[0078] Furthermore, radiolabeling of monoclonal antibody conjugates with Y90 can be performed centrally at the radiopharmaceutical manufacturing site, and the formulations will be shipped at 4–8°C to the respective transplant centers treating patients.

[0079] Absorbency radioactive label 111 In anti-CD66 radioimmunoconjugates were administered intravenously in a buffered saline solution. Sequential gamma camera images show the early blood phase and uptake by the bone marrow within 4-6 hours after injection (Figure 5).

[0080] distribution In vivo biodistribution in humans shows consistent uptake by cellular components of red blood cells, typically in the axial skeleton (vertebrae, pelvis), ribs, skull, and proximal regions of long bones. 111 Gamma images after injection of [In]-anti-CD66 are shown in Fig. 6a, and 90 Bremsstrahlung images following injection of [Y]-anti-CD66 are shown in FIG. 6b and demonstrate a similar biodistribution as each radiolabeled form of anti-CD66.

[0081] Research Question The main objective of this study is to determine whether [ 90 The objective of this study was to determine toxicity associated with the use of [Y]-labeled anti-CD66. Toxicity assessment will be measured by CTCAE version 4.0 criteria and stem cell transplantation, and a maximum tolerated radiation dose (MTD) will be established over three injected radioactivity levels.

[0082] Additionally, the study will assess clonal response (measured by serum FLC assay) by measuring changes in malignant plasma cell populations using an established and validated method of flow cytometry. Disease response, cardiac recovery, time to progression and overall survival will also be investigated while determining patient engraftment status.

[0083] Finally, this study will allow the evaluation of dosimetry models previously developed in phase I and II trials in this patient group.

[0084] Outcome Metrics / Endpoints As the sole conditioning regimen for autologous stem cell transplantation in patients with systemic AL amyloidosis 90 The toxicity of [Y]-labeled anti-CD66 monoclonal antibodies is measured using the criteria of CTCAE version 4.0.

[0085] [ 90 [Y] Clonal responses using radiolabeled anti-CD66 mAb as targeted radiotherapy will be measured by serial FLC assay. Responses will be summarized as recommended in the Consensus Guidelines for the Conduct and Reporting of Clinical Trials in Systemic Light Chain Amyloidosis.

[0086] [ 90 Y] Clonal responses to radiolabeled anti-CD66 mAb and subsequent changes in malignant plasma cell populations in the bone marrow are measured using an established and validated method of flow cytometry.

[0087] Disease response and cardiac recovery will be determined by measuring NT-proBNP levels (D100) before and after treatment.

[0088] [ 90 Y]-labeled anti-CD66 mAb to assess the effect on time and overall survival.

[0089] The same radiolabeled anti-CD66 was used, and after imaging / dosimetry90 The utility of dosimetry models developed in previous phase I and II studies using Y-labeled anti-CD66 was determined.

[0090] Autologous stem cell engraftment was evaluated by time to platelet recovery >50×10 9 / L, and neutrophils >0.5 × 10 9 / L (EBMT criteria).

[0091] To evaluate the proportion of patients who form human anti-mouse antibodies or human anti-mouse immunoglobulin antibodies (HAMA) after exposure to anti-CD66 mAb in the setting of autologous stem cell transplantation for AL amyloidosis.

[0092] Test Plan This is an open-label, Phase I / IIa, multicenter study evaluating the use of radiolabeled anti-CD66 in patients with AL amyloidosis. 1) Safety and Toxicity 2) Disease response The study was evaluated for efficacy and safety of 100 mg / kg / day of chemotherapy versus 100 mg / kg / day of chemotherapy alone. Progression from one dose level to the next will depend on the toxicity profile demonstrated, but not on disease response. Patients will be recruited from those attending the National Amyloidosis Center for disease diagnosis and monitoring, for whom high-dose therapy is a treatment option.

[0093] There are three treatment levels, which represent increasing levels of injected radioactivity: 1. 30.0MBq / kg of lean body mass [ 90 Y]-radiolabeled mouse anti-CD66 2. 40.0MBq / kg of lean body mass [ 90 Y]-radiolabeled mouse anti-CD66 3. 45.0MBq / kg of lean body mass [ 90 Y]-radiolabeled mouse anti-CD66

[0094] toxicity Patients will be recruited sequentially and treated according to the dose level in effect at that time. As a safety factor, assuming no toxicity is documented (even though patients can be recruited and consented before they are D+30 or D+60 post-transplant), the next patient will be treated at the same dose level and an interval equivalent to D+30 post-transplant must elapse before the dose level is changed at D+60 post-transplant. If no toxicity is observed in any patient, up to three patients will be recruited at the same dose level and the next dose level can be started (after an interval equivalent to D+60). If one patient develops a defined toxicity, recruitment will continue at the same dose level, but patients will be treated at the same dose level, up to a maximum of six patients. If two or more patients out of the first three patients treated at the same dose level develop toxicity, the study will be stopped. If, upon investigation, the Independent Data Monitoring Committee (IDMC) determines that the toxicity is not directly due to the radiolabeled antibody, the study may continue at the same dose level, but will be expanded to a maximum of six patients. If the IDMC determines that toxicity is directly related to the radiolabeled antibody, the study will be stopped and the infused radioactivity level will be set accordingly as the MTD. If after six patients, more than two patients exhibit toxicity attributed to the radiolabeled antibody by the IDMC, the study will be stopped, but may otherwise continue to the next dose level (as outlined above).

[0095] In the opinion of the IDMC, in the absence of specific toxicity at any infusion activity ("dose") level, the final infusion activity level may be extended to six patients to provide additional information regarding toxicity and disease response.

[0096] Disease response Disease response (changes in free light chains (FLC)) will be determined in each patient over the course of the study. Due to complications that may affect AL amyloidosis patients, if a good clinical disease response is obtained, as indicated by a decrease in FLC and clonal plasma cell populations after treatment and transplant, it will not be appropriate to clearly demonstrate the MTD (i.e., by further increase in infusion radiation activity). Optimal infusion radiation will result in a CR rate in all patients without demonstrating obvious toxicity. Results from the Phase I study will be used to inform the format of further studies (Phase II), which will aim to determine the optimal infusion radiation activity and thus the estimated bone marrow radiation dose in this particular patient population. If no toxicity is demonstrated at any infusion activity level, further evidence of disease response will be obtained by extending the third level to six patients.

[0097] patient All patients with systemic AL amyloidosis who meet the eligibility criteria for ASCT in amyloidosis and are candidates for autologous stem cell transplantation as the preferred treatment option are eligible for this study.

[0098] Selection Criteria Patients with the following characteristics are eligible for this study: 18 years or older Diagnosis of systemic AL amyloidosis as a new or recurrent disease Measurable clonal plasma cell dyscrasias Amyloid-related organ failure or syndrome -An estimated life expectancy of at least 6 months (defined at the time of study entry) Enough stem cells for two transplants Bone marrow (BM) cell count >20% Eligibility for ASCT in AL amyloidosis defined as meeting all of the following criteria: ECOG performance status of 0 or 1 Cardiac troponin-T < 0.07μg / L NYHA heart failure class <3 Consensus guidelines recommend no more than 3 organs involved in amyloidosis Creatinine clearance or isotopic GFR ≥ 30ml / min Bilirubin ≤ 1.5x and alkaline phosphatase ≤ 3x upper limit of normal AST or ALT < 2.5 × upper limit of normal Mean left ventricular wall thickness <16mm by echocardiography Absence of clinically significant amyloid-related autonomic neuropathy Absence of clinically significant amyloid-related gastrointestinal bleeding Able to provide written informed consent Women of childbearing potential should use appropriate contraception ·Intrauterine device (IUD) Hormonal-based contraception (pills, birth control injections, etc.) ·Dual barrier contraception (condom and occlusive cap, e.g., diaphragm or cervical cap with spermicide) Complete abstinence (this is the same as for dosimetry and imaging studies) 111 In] and abstaining from heterosexual intercourse until the final study visit)

[0099] Exclusion criteria Patients with the following characteristics are ineligible for this study: Overt symptomatic multiple myeloma Unknown or non-AL amyloidosis Localized AL amyloidosis (amyloid deposits are typically confined to a single organ, e.g., the bladder or larynx, in association with a clonal proliferative disorder within that organ) · Minor or incidental AL amyloid deposits in the absence of significant amyloid-related organ syndromes (e.g., isolated carpal tunnel syndrome). NYHA class III or IV heart failure Liver damage caused by amyloid, which produces bilirubin levels 1.5 times higher than the upper limit of normal Surgically removed basal cell carcinoma of the skin or other synchronous malignancies except carcinoma in situ -Pregnant, breastfeeding, or not using proper contraception Intolerance / sensitivity to any investigational drug Known positive human anti-mouse antibodies or human anti-mouse immunoglobulin antibodies (HAMA) Failure to provide written informed consent -Participate in another IMP exam

[0100] Exam evaluation Treatment - First visit Dosimetry and Imaging Premedicating patients before administration of RIC Patients receiving animal-derived antibodies may experience symptoms such as fever, chills, and myalgia, even in the absence of antibodies against a particular species, e.g., HAMA. Accumulated clinical experience with anti-CD66 indicates that side effects from antibody infusions are rare, reported to occur in 0.5–1.0 per 10,000 infusions.

[0101] Resuscitation facilities must be immediately available; this includes equipment for respiratory support - oxygen supply, ventilator, masks and bags. Adrenaline must be available and ready to be administered.

[0102] All subjects will be premedicated 30-60 minutes prior to oral administration of radiolabeled anti-CD66 consisting of both 4 mg chlorpheniramine and 1 g paracetamol, and the use of steroids (e.g., hydrocortisone) will be avoided unless significant symptoms occur, in which case 50-100 mg of hydrocortisone will be administered. If the use of radiolabeled anti-CD66 is associated with symptoms in the majority of subjects, the use of steroids as part of the premedication will be investigated.

[0103] [ 111 Administration and dosimetry of [In]-labeled RIC (2-4 weeks after stem cell harvest) - Formulation A The small imaging dose of approximately 185 MBq [ 111 In]-labeled anti-CD66 is given.

[0104] Treatment - 2nd visit [ 90 Administration of [Y]-labeled RIC (day 14) Infusion of labeled anti-CD66 should occur at least 1 week after dosimetry and will be given via a central venous line or, if not inserted, a peripheral cannula, with an initial infusion rate of 5 mg / hour for the first 5 minutes, and if tolerated, the rate may be increased to 10 mg / hour. If the subject develops significant symptoms such as tightness in the throat, difficulty breathing, severe chills, or paralysis, the rate may need to be reduced or the infusion stopped. Once the infusion is complete, the line will be flushed with 10-20 ml of saline.

[0105] At these infusion rates, a total of 2 mg of labeled antibody would take 12 minutes to infuse.

[0106] Treatment - 3rd visit (from the 7th day 90 Y] 0 days after The patient will be investigated and started on prophylactic antibiotics (ciprofloxacin 250 mg bd, acyclovir 400 mg bd and fluconazole 100 mg od).

[0107] Autologous stem cell reinfusion (day 0) All patients will be transplanted at the transplant center using inpatient or outpatient facilities as needed. 90 Based on experience from Phase I and II trials using anti-CD66, patients' peripheral blood counts were [ 90Y] is expected to decline starting on day 7 after infusion and reach a nadir on days 8-10 [equivalent to days 6-4 before transplant]. Patients will be admitted to the hospital if they are not already being treated as inpatients. After stem cell transplant (day 0), they will be assessed daily by the study team for adverse events and appropriate need for additional antibiotics or blood products. Patients will be discharged after adequate hematopoietic engraftment and recovery from infection, and independent of blood product support. Patients will be followed up on days 30 and 100 after discharge. Study follow-up will end on day 100, and follow-up will continue off-study according to standard medical practice.

[0108] Time to disease recurrence or progression and time to next treatment will not be included as part of the formal assessment within the scope of the study. However, all patients undergoing ASCT for AL amyloidosis will have regular long-term follow-up and will be regularly examined by their referring consultant.

[0109] result The first three patients with AL amyloidosis who relapsed after being treated with high-dose melphalan and subsequent ASCT were 111 After appropriate dosimetry with In-labeled preparations, 30MBq / kg 90 Treated with Y-labeled preparation.

[0110] Three patients 90 No side effects were observed during conditioning with the Y-labeled preparation, nor were there any serious adverse reactions (SAES) or unexpected severe adverse reactions (SUSAR). In all three patients, a decrease in clonal free light chains was observed. In one case, a complete response was observed with sustained normalization of FLC and improvement of clinical symptoms and disease parameters of AL amyloidosis. The study was approved by the Data and Safety Committee to continue to the next infusion activity level.

[0111] These findings are absolutely unique and unexpected. Inducing disease regression as shown by reduction in FLC without side effects is a remarkable result, which will greatly benefit patients suffering from AL amyloidosis.

[0112] Figure 7 shows the concentration of serum free light chains over time in a patient treated with RIC at a dose of 30 MBq / kg. FLC concentration, a reliable biomarker for AL amyloidosis, decreases from 80 mg / l to approximately 25 mg / l within one month. FLC levels are maintained at 10-30 mg / l (typical values ​​in healthy humans) for several months. One patient had a complete response, which was analyzed by normalization of free light chains, bone marrow biopsy and determination of minimal residual disease. The patient was in biochemical complete response for 15 months after transplantation.

[0113] Two other patients also showed a significant decrease in FLC levels after RIC treatment.

Claims

1. 1. A pharmaceutical composition comprising a radioimmunoconjugate (RIC) for use as a medicament in bone marrow conditioning, comprising: comprising a CD66 binding component and a radionuclide, the CD66 binding component is an antibody; the radionuclide is attached to the CD66 binding component via a chelator; the chelator is covalently attached to the CD66 binding component; The RIC has the following structure: [Case 1] (CD66 binding component-NH-CS-NH-Bn-CHX-A″-DTPA) and salts thereof, the pharmaceutical composition is for administration to a patient who is ineligible for treatment with high-dose melphalan prior to HSCT; and / or The pharmaceutical composition is for administration to a patient who has been treated with induction therapy but has shown disease progression or hematological response; and The bone marrow conditioning is bone marrow conditioning at the time of stem cell transplantation and does not include administration of additional antitumor or immunosuppressive agents for at least 4 weeks before and / or after stem cell transplantation; Pharmaceutical compositions.

2. 1. A pharmaceutical composition comprising a radioimmunoconjugate (RIC) for use in the treatment of a bone marrow-related disease, comprising: the bone marrow-related disease is AL amyloidosis; comprising a CD66 binding component and a radionuclide, the CD66 binding component is an antibody; the radionuclide is attached to the CD66 binding component via a chelator; the chelator is covalently attached to the CD66 binding component; and The RIC has the following structure: [Case 2] (CD66 binding component-NH-CS-NH-Bn-CHX-A″-DTPA) and salts thereof, the treatment of the bone marrow-related disease further comprises stem cell transplantation and does not comprise administration of additional anti-tumor or immunosuppressive agents prior to and / or for at least 4 weeks after stem cell transplantation; Pharmaceutical compositions.

3. 3. The pharmaceutical composition of claim 2 comprising an imaging radionuclide.

4. 3. The pharmaceutical composition of claim 1 or 2, wherein the radionuclide is a therapeutically active radionuclide.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the CD66 binding component is BW250 / 183.

6. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered at a dose of about 10 MBq / kg lean body weight (lbw) or more.

7. The treatment of bone marrow-related diseases further comprises stem cell transplantation; and The pharmaceutical composition according to any one of claims 1 to 6, wherein the pharmaceutical composition is for administration 6 to 16 days before stem cell transplantation.

8. The pharmaceutical composition is for administration to a patient who has undergone stem cell transplantation after treatment with high dose melphalan, but has shown disease progression; and / or 8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is for administration to a patient eligible for HSCT.

9. The pharmaceutical composition is for administration to patients who have been treated with induction therapy but have shown disease progression or hematological response, and / or The pharmaceutical composition of any one of claims 2 to 8, wherein the pharmaceutical composition is for administration to a patient ineligible for treatment with HD-melphalan preceding HSCT.

10. Treatment of AL amyloidosis is (a) optionally, prior to step (b), administering an imaging RIC to the patient for 2-10 days; (b) administering a therapeutic RIC to the patient for 6 to 16 days prior to step (c); and (c) Transplanting autologous or allogeneic stem cells.

10. The pharmaceutical composition according to any one of claims 2 to 9, comprising:

11. 7. The pharmaceutical composition of any one of claims 1 and 4 to 6, wherein said bone marrow conditioning comprises immune ablation to prevent graft rejection and / or to reduce the number of defective cells in the bone marrow.

12. 9. The pharmaceutical composition of any one of claims 1 and 4 to 8, wherein the stem cell transplant is autologous or allogeneic.

13. The following structure: [C3] A radioimmunoconjugate (RIC) of (CD66 binding component-NH-CS-NH-Bn-CHX-A″-DTPA) and salts thereof, wherein the CD66 binding component is an antibody.

Citation Information

Patent Citations

  • Targeted radioactive compound for human CD66 for the treatment of disorders

    WO2011144744A1